References: Anderson PL. The ABCs of pharmacokinetics. http://www.thebody.com/content/art875.html. Accessed April 2018. • Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413-420. • Data on file. 2.5 Clinical Overview. Bayer; 2017. • Data on file. Tx Review 1018. Bayer; 2018. • Dhillon S, Gill K. Basic pharmacokinetics. In: Dhillon S, Kostrzewski A, eds. Clinical Pharmacokinetics. London, UK: Pharmaceutical Press; 2006. • Ivens IA, Baumann A, McDonald TA, Humphries TJ, Michaels LA, Mathew P. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia. 2013;19(1):11-20. • Jivi® Prescribing Information. Whippany, NJ: Bayer LLC; 2018. • Ratain MJ, Plunkett WK Jr. Principles of pharmacokinetics. In: Kufe DW, Pollock RE, Weichselbaum RR, et al, eds. Holland-Frei Cancer Medicine. 6th ed. Hamilton, Ontario: BC Decker, Inc; 2003. • Shah A, Solms A, Wiegmann S, et al. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann Hematol. 2019;1-10. https://link.springer.com/article/10.1007%2Fs00277-019-03747-2. Published June 24, 2019. Accessed June 25, 2019. • Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315-329. • Webster R, Elliot V, Park BK, Walker D, Hankin M, Taupin P. PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese FM, ed. PEGylated Protein Drugs: Basic Science and Clinical Applications. Basel, Switzerland: Birkhäuser Verlag/Switzerland; 2009:127-146.